title: [Oral antidiabetic drugs in chronic renal disease].
abstract: Decline in renal function may increase plasma concentration of several drugs - including oral antidiabetics - with a possible need for dose adjustment in this patient population. In this review, the pathophysiology and progression of diabetic kidney diseases is summarized. Guidance is given about appropriate administration of oral antidiabetic drugs in chronic kidney diseases, based on approved product label information. In addition to pioglitazon, recent availability of the new dipeptidyl peptidase-4 inhibitor linagliptin provides another option for diabetic patients with renal impairment without the need for dose reduction due to its predominant enterohepatic elimination.
authors.affiliation: Semmelweis Egyetem, Általános Orvostudományi Kar II. Belgyógyászati Klinika Budapest. somogyi.aniko@med.semmelweis-univ.hu
authors.forename: Anikó
authors.initials: A
authors.lastname: Somogyi
mesh_terms: D000284:Administration, Oral; D001786:Blood Glucose / Q000378:metabolism*; D003928:Diabetic Nephropathies / Q000097:blood / Q000188:drug therapy / Q000378:metabolism* / Q000517:prevention & control*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000008:administration & dosage; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000378:metabolism; D000069476:Linagliptin; D000077205:Pioglitazone; D011687:Purines / Q000008:administration & dosage; D011799:Quinazolines / Q000008:administration & dosage; D045162:Thiazolidinediones / Q000008:administration & dosage
chemical_list: D001786:Blood Glucose; D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D011687:Purines; D011799:Quinazolines; D045162:Thiazolidinediones; D000069476:Linagliptin; D000077205:Pioglitazone